FLHLF News and Press, Filament Health From 04/25/22

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences , the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Co...

FILAMENT HEALTH AND PSYENCE ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR NATURAL PSILOCYBIN PRODUCTS Canada NewsWire The partnership leverages Psyence's expertise in fungi cultivation and palliative care as well as Filament's expertise in the manufacture of pharmaceuti...

VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc ( CSE: PSYG | OTCQB: PSYGF ) (“Psyence”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, and Fila...

FILAMENT HEALTH IS ISSUED PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC , April 13 , 2022 /CNW/ - Filament Hea...

FILAMENT HEALTH ANNOUNCES PRE-IND MEETING WITH UNITED STATES FOOD AND DRUG ADMINISTRATION Canada NewsWire VANCOUVER, BC , April 12, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinica...

FILAMENT HEALTH TO PARTICIPATE IN PROMINENT PSYCHEDELIC INVESTOR CONFERENCES IN APRIL 2022 Canada NewsWire VANCOUVER, BC , April 7, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage ...

Filament Made Substantial Progress During 4Q21. Filament Health reported a full year loss of $9.3 million or $(0.06) per share. During the quarter, Filament advanced its clinical pipeline, made licensing agreements, and strengthened its intellectual property. The cash balance at December 31, 2...

Filament Health press release (OTC:FLHLF): FY Cash and cash equivalents of C$4.6 million and working capital of C$5.0 million as of December 31, 2021. For further details see: Filament Health reports FY results

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire Filament announced FDA approval for the first clinical trial using naturally-sourced psychedelic substances in November 2021 The Company signed multipl...

Filament Health (FLHLF) CEO Ben Lightburn provides a preview of their upcoming presentation at NobleCon18 NobleCon18 - Noble Capital Markets 18th Annual Small and Microcap Investor Conference - April 19-21, 2022 - Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts...